The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities - Takeaways - MDSpire

The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities

  • By

  • Emily Jones

  • Kiki Cano-Gamez

  • June 23, 2026

  • 0 min

Share

  • 1

    Cell-free DNA (cfDNA) plays a significant role in the immune activation associated with systemic lupus erythematosus (SLE).

  • 2

    Deficiencies in DNASE1L3 lead to altered cfDNA fragmentation and increased immunogenic potential in SLE patients.

  • 3

    Aberrant cfDNA can trigger type I interferon responses and stimulate anti-double-stranded DNA antibody production.

  • 4

    cfDNA features, such as fragment length and epigenetic modifications, can serve as biomarkers for monitoring SLE disease activity.

  • 5

    Large-scale validation and standardization of cfDNA insights are essential for advancing precision medicine in SLE.

Original Source(s)

The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities

  • by Emily Jones, Kiki Cano-Gamez

  • June 23, 2026

Related Content

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease

Systemic lupus erythematosus–driven accelerated atherosclerosis: the immune–metabolic–vascular axis and therapeutic implications

Distinct IgM and IgG autoantibody profiles characterize incomplete and classified systemic autoimmune diseases